Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06685757 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
A Phase 3 study of Antibody-mediated Rejection, sponsored by Biogen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT06685757: Recruiting Phase 3 study of Antibody-mediated Rejection, sponsored by Biogen.
NCT06685757 is a Phase 3 study of Antibody-mediated Rejection that is actively recruiting participants, run by Biogen. The registered enrollment target is 120 participants, below the 148-participant average among 5 other Antibody-mediated Rejection trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06685757, a Phase 3 study of Antibody-mediated Rejection, is actively recruiting participants, sponsored by Biogen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
In this study, researchers will learn more about the use of felzartamab in kidney transplant patients who have antibody-mediated rejection, also known as AMR. Kidney transplants can save lives for people with kidney failure. But even after a successful transplant, the body's immune system can sometimes attack the new kidney. Antibody-mediated rejection (AMR) is when a person's immune system attacks a transplanted organ, like a new kidney. In the person receiving the transplant, their immune system creates specific antibodies. Antibodies are proteins that help the body fight infections. In people with AMR, these antibodies mistakenly see the new organ as a threat and damage its blood vessels. This can cause the new organ to fail. In this study, researchers will learn more about how a study drug called felzartamab affects people with AMR. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce antibodies, helping to lower their buildup in the kidneys. The main goal of this study is to compare how felzartamab works in participants with kidney transplants who experience AMR compared to a placebo. A placebo is something that looks like the study drug but does not contain any medicine. A placebo is also given in the same way as the study drug. All participants in this study will have active AMR or AMR that has lasted for at least 6 months after their kidney transplant. The main question that researchers want to answer is: • How many participants have biopsy results showing that their transplanted kidney tissue looks normal or near normal after 24 weeks of treatment? Researchers will also learn about: * How long it takes before the participants' disease gets worse * How long the participants' urine protein levels stay low * Kidney biopsy scores to check for blood vessel inflammation at 6 months and 1 year * How many people have no blood vessel inflammation at these times * Changes in d
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Felzartamab
Study Locations (20)
California
- University of Southern California - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- UCLA - Los Angeles
- Providence Healthcare - Orange
- Loma Linda - San Bernardino
- California Pacific Medical Center - San Francisco
- University of California, San Francisco - San Francisco
Ohio
- University of Cincinnati - Cincinnati
- Cleveland Clinic - Cleveland
- The Ohio State University - Columbus
Colorado
- University of Colorado - Aurora
Illinois
- University of Chicago - Chicago
Kansas
- University of Kansas - Kansas City
Louisiana
- Tulane University Health Sciences Center - New Orleans
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-12-03 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 3 |
What NCT06685757 shows while recruiting
NCT06685757 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 148-participant average among 5 other Antibody-mediated Rejection trials with a reported enrollment target (19% lower).
The record links to 1 condition, with Antibody-mediated Rejection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06685757 names 20 study sites across 12 states, led by California, Ohio, Colorado.
Frequently Asked Questions
What is clinical trial NCT06685757 about?
NCT06685757 is a clinical study titled "A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)". In this study, researchers will learn more about the use of felzartamab in kidney transplant patients who have antibody-mediated rejection, also known as AMR. Kidney transplants can save lives for people with kidney failure. But even after a successful transplant, the body's immune system can someti...
What is the current status of trial NCT06685757?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2024-12-03. Estimated completion is 2027-06-01.
What conditions does trial NCT06685757 study?
This clinical trial studies the following conditions: Antibody-mediated Rejection.
What interventions are being tested in trial NCT06685757?
The interventions under investigation include: Placebo (DRUG), Felzartamab (DRUG).
Who is sponsoring clinical trial NCT06685757?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06685757 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Kansas, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Antibody-mediated Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biorepository and Registry for Plasma Exchange Patients
RECRUITING
-
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
RECRUITING · Phase 2
-
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
RECRUITING · Phase 2
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
VIRTUUS Children's Study
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI